When Jonathan Kay, MD, attends a medical lecture, he does more than just listen to the speakers or watch their presentations. He typically whips out his pen and draws a caricature of someone in the room. Dr. Kay is a professor of medicine and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology…
I just couldn’t believe it. Like all of you, I receive many requests to see patients urgently. And like all of you, I can’t possibly accommodate all of those requests. So I triage: I look through the referrals and try to differentiate patients who want to be seen from those who need to be seen….
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Working with the AMA provides a megaphone to amplify rheumatology’s voice at both federal and state levels. This year is the AMA’s next five-year membership review. Join the AMA or renew your membership now to keep the ACR represented in AMA policy bodies.
During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…
Professional practices, state societies and other organizations can support RheumPAC’s work with corporate funds through the RheumPAC Advocacy Fund.
Research indicates mRNA vaccination for SARS‐CoV‐2 infection may induce a T cell response in vulnerable, immunocompromised patient populations being treated with rituximab.
As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.
On July 9, U.S. President Joe Biden issued an Executive Order designed to promote competition in the U.S. economy. The order includes 72 initiatives related to various aspects of the economy, including prescription drugs and health insurance.1 For prescription drugs, Americans pay more than 2.5 times as much for the same prescription drugs as patients…